Cancer Genetics jumps on upbeat Feltl note

Shares of Cancer Genetics (CGIX +4.8%) — which got a big lift last week on an upbeat Aegis initiation — are on the move after Feltl's Ben Haynor ups his price target to $30.50 from $17.50.

Among the catalysts cited by Haynor: CGIX's expanded relationship with Roche and the debut of the Mantle Cell Lymphoma array.

Comments (1)
  • EvanFry
    , contributor
    Comments (3) | Send Message
    Aegis and Feltl were the two underwriters on the IPO and follow up offering; of course they are going to give CGIX an upgrade. Also how does Feltl go from $17.5 to $30 in such a short period on such minor news. Appears to be a typical pump by a few sell side analysts.
    2 Oct 2013, 03:30 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs